Építés alatt – nem éles oldal
Belépés
Még nem keres résztvevőt itt: SpanyolországFázis nélkül

Impact of CMV-Specific Immune Reconstitution at the End of Letermovir Prophylaxis on the Development of Late Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Recipients (INMUNOEND)

A legfontosabb adatok

Ki végzi
Maimónides Biomedical Research Institute of Córdoba
Hol
Córdoba (Spanyolország)A helyszín megnézése
Azonosító
Állapot
Toborzás még nem indult
Résztvevők
123 fő, tervezett
Kezdés
2025. dec. 1.
Várható befejezés
2027. szept.
A vizsgálat típusa
Megfigyeléses
A vizsgált kezelések
  • Periodic immunological monitoring of CMV-specific immune reconstitution will be performed using QTF-CMV
A regiszteradat frissítve
2025. november 28.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults who have had their first stem cell transplant from a donor and carry past CMV infection. They must get letermovir to prevent CMV in the first 100 days. The study only watches and tests blood; it gives no new treatment.

Életkor
Over 18 years (record: age >18 years; minimum age 18 Years).
Nem
All sexes can join.
A betegség stádiuma
First allogeneic (donor) stem cell transplant, from bone marrow, blood or cord blood. Joining must be within the first 28 days after transplant.
Korábbi kezelés
Must have a plan for letermovir (LTV) prevention, starting within 28 days after transplant up to 100 days after. Cannot join after a previous donor stem cell transplant; an earlier transplant of your own cells is allowed. Cannot join after ganciclovir, valganciclovir, foscarnet, or high doses of acyclovir, valacyclovir or famciclovir in the 14 days before. Cannot join after cidofovir, CMV hyperimmune immunoglobulin or a trial CMV drug in the 30 days before.
Biomarker vagy leletérték
Positive CMV IgG blood test (past CMV infection) at the time of transplant.

A részvétel fő kizáró okai

  • Negative CMV IgG test at the time of transplant
  • CMV disease in the 6 months before joining, or early CMV treatment needed in the month before
  • Known or suspected allergy to letermovir or its ingredients
  • Severe liver failure (Child-Pugh class C) or an inborn immune disorder before transplant
  • Taking part in a trial of CMV vaccines, other trial CMV drugs or monoclonal antibodies

A regiszter feltételei, szó szerint

Mind a 15 feltétel megnézéseKevesebb

Ki vehet részt

  • Age >18 years
  • CMV seropositivity (positive IgG) in the recipient at the time of SCT
  • First allogeneic hematopoietic stem cell transplant recipient (bone marrow, peripheral blood, or cord blood)
  • Within the first 28 days post-SCT at the time of inclusion
  • Indication for LTV prophylaxis within the first 28 days post-transplant up to 100 days post-SCT, according to the criteria established in each center

Ki nem vehet részt

  • CMV seronegativity (negative IgG) in the recipient at the time of transplant
  • Previous allogeneic stem cell transplant (patients with a prior autologous transplant are allowed to be included)
  • History of CMV disease in the 6 months prior to inclusion
  • Need for preemptive therapy in the month prior to inclusion in the study
  • Received any of the following in the 14 days prior to inclusion: Ganciclovir, valganciclovir, foscarnet, acyclovir (at doses >3200 mg orally per day or >25 mg/kg IV per day), valacyclovir (at doses >3000 mg orally per day), famciclovir (at doses >1500 mg orally per day)
  • Received any of the following in the 30 days prior to screening: Cidofovir, CMV hyperimmune immunoglobulin, any CMV antiviral in the investigational phase
  • History of primary immunodeficiency prior to transplant
  • Participation in a clinical trial involving the administration of CMV vaccines, other investigational CMV drugs, or monoclonal antibodies
  • Suspected or confirmed hypersensitivity reaction to the LTV formulation or any of its components
  • Severe hepatic insufficiency (defined as Child-Pugh class C)

Helyszínek itt: Spanyolország

  • Hospital Universitario Reina SofiaCórdoba, SpanyolországToborzás még nem indult

A vizsgálatról

Mit akar kideríteni a vizsgálat

Cytomegalovirus (CMV) infection is a common complication in patients undergoing hematopoietic stem cell transplantation (SCT). Fixed-duration letermovir (LTV) prophylaxis during the first 100 days post-SCT is effective and safe in preventing this infection, although it may be associated with a delay in CMV-specific immune reconstitution. Hence, it is needed a study to evaluate whether the absence of CMV-specific immune reconstitution at the end of LTV prophylaxis is associated with the development of late infection. This could facilitate the individualization of CMV prophylaxis duration in these patients.

A teljes eredeti leírásKevesebb

Methods and analysis: INMUNOEND is a multicenter, prospective, observational, non-interventional study including CMV seropositive patients undergoing allo-SCT who receive LTV prophylaxis during the first 100 days post-SCT. Immunological and virological monitorization will be conducted until day +200 post-SCT. The primary outcome variable is the percentage of patients who develop clinically significant CMV infection up to day +200 post-SCT after completing LTV prophylaxis. Data collected will include: baseline characteristics of the hematological diseases and comorbidities, variables related to SCT (i.e. engrafment, graft-versus-host disease, use of letermovir and CMV replication) and variables related to CMV-specific immune reconstitution.

A vizsgálat csoportja

  • patients undergoing allogenic-SCT who receive LTV prophylaxis with letermovir

    Kezelés: Periodic immunological monitoring of CMV-specific immune reconstitution will be performed using QTF-CMV

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Impact of CMV-Specific Immune Reconstitution at the End of Letermovir Prophylaxis on the Development of Late Cytomegalovirus Infection in HSCT Recipients (INMUNOEND): a Protocol for a Prospective, Observational, Multicenter Study
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Publikációk
A regiszteradat frissítve
2025. november 28.